The iconic rise of Sildenafil presented a considerable chance for the market, but its exclusivity has lapsed , creating a complex landscape. Generic versions have entered the arena, diminishing revenues and putting a squeeze on profit percentages . While major healthcare companies maintain a foothold in this sector , the outlook seems unclear by in